Bruker and the Genome British Columbia Proteomics Centre at the University of Victoria Announce Collaboration on Development of

  Bruker and the Genome British Columbia Proteomics Centre at the University
  of Victoria Announce Collaboration on Development of High Throughput iMALDI

    Initial Developments are Targeted at Tests for Diabetes and Hemoglobin

Business Wire

VICTORIA, British Columbia -- April 18, 2013

Bruker and the University of Victoria-Genome British Columbia Proteomics
Centre (UVic GBC Proteomics Centre) have announced a collaborative effort for
the development and validation of high-throughput assays for determining
hemoglobin variants and diabetes risk, using Bruker´s MALDI Biotyper platform
for clinical mass spectrometry, and based on intellectual property developed
at the UVic GBC Proteomics Centre.

"Dr. Christoph Borchers, director of the University of Victoria-Genome British
Columbia Proteomics C ...

"Dr. Christoph Borchers, director of the University of Victoria-Genome British
Columbia Proteomics Centre." (Photo: Business Wire)

Diabetes: The liquid chromatography, immunoassay and electrophoresis-based
methods which are currently used to screen and monitor for blood disorders are
expensive, laborious and time-consuming. In 2009, the Expert Committee of the
International Diabetes Foundation recommended the use of the hemoglobin-based
A1c (hbA1c)  test as the “method of choice” for diagnosing and monitoring
diabetes. In contrast to previous assays, it is expected that the new MALDI
(Matrix-Assisted Laser Desorption Ionization) TOF-MS (time-of-flight mass
spectrometry) based test for hbA1c and genetic hemoglobin variants designed
for use on the MALDI Biotyper platform will provide advantages with regards to
specificity, accuracy, speed of analysis and cost per analysis. These
performance and cost advantages, coupled with the ease of use and speed of a
MALDI-TOF assay, are anticipated to result in higher patient screening rates,
which is especially important in the case of diabetes where early detection of
at-risk subjects can lead to the prevention of disease onset. Complications of
undiagnosed or poorly controlled diabetes include cardiovascular disease,
chronic renal failure, retinal damage which can lead to blindness, several
kinds of nerve damage, and micro-vascular damage.

Hemoglobin Variants: Some well-known genetic hemoglobin variants are
responsible for diseases such as sickle-cell anemia, C disease, and a separate
class of diseases known as thalassemias. Diabetes is also reflected in the
blood by an increase in the level of glycated hemoglobin, which is measured in
the hbA1c test. In general, individuals with inherited blood disorders are
physiologically vulnerable and are at higher risk of infection, stroke, heart
failure, liver and acute chest syndrome. Late diagnosis of diseases such as
sickle-cell anemia can result in delay of treatment and irreversible damage to
major organs, including increased risk of stroke or kidney damage.

The MALDI Biotyper platform is already in widespread clinical use with over
800 systems installed globally. Applications include clinical routine
microbial identification, environmental and pharmaceutical analysis,
taxonomical research, food and consumer product safety and quality control, as
well as marine microbiology. The MALDI Biotyper is available in a
research-use-only version, as well as in an IVD-CE version according to EU
directive EC/98/79 in various European countries, and as a Class 1 Medical
Device to clinical microbiology sites in Canada. In the United States of
America the MALDI Biotyper is available for research use only, not for use in
diagnostic procedures.

Dr. Gary Kruppa, Vice President for Business Development at Bruker Daltonics,
stated: “The MALDI Biotyper is a versatile, robust, benchtop system that is
well suited for use in clinical laboratories as evidenced by its large
installed base. We are very pleased to be working with the world-class team of
researchers at the UVic GBC Proteomics Centre on the development and
validation of high throughput iMALDI tests to further broaden the clinical
applications of the MALDI Biotyper platform.”

Professor Christoph Borchers, Director of the GBC UVic Proteomics Centre,
commented: “The collaboration with Bruker is an excellent match. We believe
that further development of our MALDI and immunoMALDI (iMALDI) technology will
lead to commercialization of MALDI-TOF based tests for a number of important
diseases. Developing and validating these tests in collaboration with Bruker
gives us a partner ready to deploy such tests on the clinically accepted MALDI
Biotyper platform, which will reduce our time to market.”

About Bruker Corporation

Bruker Corporation (NASDAQ: BRKR) is a leading provider of high-performance
scientific instruments and solutions for molecular and materials research, as
well as for industrial, diagnostics and applied analysis. For more
information, please visit

ABOUT UVic Genome-BC Proteomics Centre

The UVic-Genome BC Proteomics Centre, located at UVic’s Vancouver Island
Technology Park in Victoria, British Columbia, Canada, has been providing
protein analytical services to academic, biotechnology, pharmaceutical and
government laboratories worldwide since 1982. Supported in part by a
collaborative relationship between the University of Victoria and Genome
British Columbia, the centre is a not-for-profit proteomics facility. For more
information: Dr. Christoph Borchers, Director: E:,
T: +1 (250) 483-3221.

For more information in iMALDI:

Photos/Multimedia Gallery Available:



Bruker Daltonics
Gary H. Kruppa, Ph.D., +1-978-663-3660, x1227
Vice President of Business Development
Press spacebar to pause and continue. Press esc to stop.